Protagonist Therapeutics (NASDAQ: PTGX) has recently received a number of price target changes and ratings updates:
- 8/7/2024 – Protagonist Therapeutics had its price target lowered by analysts at JMP Securities from $45.00 to $43.00. They now have a “market outperform” rating on the stock.
- 8/7/2024 – Protagonist Therapeutics had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a “buy” rating on the stock.
- 7/25/2024 – Protagonist Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $48.00. They now have an “overweight” rating on the stock.
- 7/24/2024 – Protagonist Therapeutics had its price target raised by analysts at BTIG Research from $41.00 to $51.00. They now have a “buy” rating on the stock.
- 6/17/2024 – Protagonist Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $45.00 price target on the stock.
- 6/14/2024 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Protagonist Therapeutics Stock Down 1.2 %
Shares of NASDAQ:PTGX traded down $0.42 during trading on Wednesday, reaching $35.79. 602,380 shares of the company’s stock traded hands, compared to its average volume of 789,789. Protagonist Therapeutics, Inc. has a fifty-two week low of $13.72 and a fifty-two week high of $42.67. The company has a 50-day simple moving average of $34.55 and a 200-day simple moving average of $30.29. The firm has a market cap of $2.10 billion, a PE ratio of 14.67 and a beta of 2.13.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $40.00 million. On average, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.24 EPS for the current year.
Insider Activity at Protagonist Therapeutics
Institutional Investors Weigh In On Protagonist Therapeutics
A number of large investors have recently modified their holdings of the company. TD Asset Management Inc boosted its holdings in shares of Protagonist Therapeutics by 36.7% in the 2nd quarter. TD Asset Management Inc now owns 148,302 shares of the company’s stock valued at $5,139,000 after buying an additional 39,850 shares in the last quarter. Cannon Global Investment Management LLC acquired a new position in Protagonist Therapeutics in the second quarter valued at $2,422,000. Bank of New York Mellon Corp grew its holdings in shares of Protagonist Therapeutics by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock worth $7,079,000 after purchasing an additional 17,065 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Protagonist Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 37,880 shares of the company’s stock valued at $1,313,000 after purchasing an additional 2,985 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at about $379,000. 98.63% of the stock is owned by hedge funds and other institutional investors.
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Featured Stories
- Five stocks we like better than Protagonist Therapeutics
- How to Calculate Options Profits
- What Are Bonds? A High-Level Overview
- Stock Splits, Do They Really Impact Investors?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- What Does a Stock Split Mean?
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.